Illustrative image – not actual.
Odisha is poised to become a pharmaceutical manufacturing hub, enhancing employment and economic growth in the state. In preparation for the upcoming mega investment summit, Utkarsh Odisha: Make-in-Odisha Conclave 2025, the state government has established the Odisha Pharmaceutical Development Cell (OPDC).
This cell, led by the Chief Secretary, will act as a bridge between the state and potential investors, fostering collaborations and expediting investments. The OPDC will formulate a comprehensive Odisha Pharmaceutical Policy 2025 and implement a roadmap for a dedicated pharmaceutical special economic zone (SEZ). A pharmaceutical CEO conclave has been scheduled to attract multinational and national industry leaders, enabling discussions on investment opportunities within Odisha.
Plans are underway to establish dedicated pharmaceutical parks featuring world-class infrastructure, streamlined regulatory clearances, and financial incentives for investors. Potential locations for these parks include Bhubaneswar, Cuttack, and Balasore due to their strategic connectivity and existing industrial base. Additionally, a world-class pharmaceutical SEZ is being developed in the Khurda-Balasore corridor with state-of-the-art facilities.
Odisha currently hosts 22 pharmaceutical formulations manufacturing units, 22 medical device/equipment manufacturers, five liquid medical oxygen plants, and one active pharmaceutical ingredient (API) unit. Notable companies such as Sapigen Biologix (Bharat Biotech) and Infinix have already established units in the state. The focus now is to expand the number of API units and drug manufacturing companies to bolster the pharmaceutical ecosystem further.
